fda warning compounded semaglutide safety 2024 2025 restricts non-approved GLP-1 weight loss products As interest in weight loss

Diabetes Ther (2019) 10(6):203544

How has this drug affected patients involved in clinical trials

While reduced appetite is the mechanism driving weight loss, extreme caloric restriction creates problems that extend beyond just feeling tired

But just because someones mood changes while they are taking the medications doesnt mean the drugs themselves caused the change

These results are particularly notable because they demonstrate that retatrutide's weight loss translates into meaningful clinical improvements, in this case, significant pain reduction for people with obesity-related joint problems

Discuss potential side effects and your tolerance for them